( Efficacy and Safety of Gene Therapy in...)AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy,Health

Efficacy and Safety of Gene Therapy in Lipoprotein Lipase Deficiency Established

Amsterdam, The Netherlands - May 31, 2007 - Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, reported positive Phase I/II clinical trial results with its lead product AMT-010 (now referred to as AMT-011) in Complete Lipoprotein Lipase (LPL) deficient patients at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle. The study's lead investigator is Erik S.G. Stroes, MD, PhD, from the University of Amsterdam Medical Center in The Netherlands.

Ronald Lorijn, CEO of AMT, said, "We believe these excellent results may represent an important milestone for the entire field of gene therapy and for the many patients who today cannot be treated. Our clinical success and the breakthrough in our production platform place us squarely at the forefront of the gene therapy field that is finally coming into its own."

AMT's products rely on a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Study design

The primary goal of the study presented at the ASGT was to investigate if AMT-010 reduces the elevated triglyceride (fat) levels and the associated risk of pancreatitis in Complete LPL deficient patients. The study design was an eight-patient open label dose-escalating study (low and mid dos
'"/>